X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

API PA by API PA
21st July 2025
in News
ChiRhoClin LogiCare3PL Partners for Drug Distribution

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

LogiCare3PL, a division of BioCare, Inc., has announced a partnership with ChiRhoClin, Inc., a recognized leader in pancreatic and gastrointestinal diagnostics. This strategic move underscores both organizations’ dedication to ensuring the reliable, timely delivery of critical diagnostic treatments to patients nationwide. The company will be the only third-party logistics (3PL) provider for ChiRhoStim®, ChiRhoClin’s flagship product.

As a nationally accredited orphan drug logistics expertise, LogiCare3PL brings extensive expertise in handling high-value, small-batch pharmaceuticals. ChiRhoClin, LogiCare3PL partners will enhance ChiRhoClin’s distribution capabilities, while maintaining the respective mutual commitment to an exceptional focus on high-touch service and patient-centered care. With the support of LogiCare3PL, ChiRhoStim® distribution will be carried out through a network with uncompromising commitments to accuracy and reliability.

Kevin Kissling, Vice President and General Manager of LogiCare3PL, expressed pride in supporting ChiRhoClin’s vital mission. “We’re proud to support ChiRhoClin in distributing ChiRhoStim®, a diagnostic product that plays a vital role in patient care,” Kissling said. “Our team appreciates the importance of reliability and precision in handling sensitive therapies like ChiRhoStim®, and we are committed to delivering a seamless and dependable experience for ChiRhoClin’s customers.”

Supporting the commitment are LogiCare3PL’s two fully accredited distribution centres, which have been located in Tempe, Arizona, and Olive Branch, Mississippi. The distribution centers are customised for high-value pharmaceutical logistics, precision, and compliance, fully accredited by the National Association of Boards of Pharmacy® (NABP®), compliant with cGMP regulations and ready to support both domestic and international distribution requirements as ChiRhoClin, LogiCare3PL partners for ChiRhoStim® distribution.

Skip Purich, CEO of ChiRhoClin, Inc., highlighted the value of the partnership, stating, “The LogiCare3PL team has been a proactive and engaged partner as we prepared to distribute ChiRhoStim® through the company’s distribution network. Their experience in orphan drug logistics has been critical to establishing a strong foundation for this launch, and we’re confident this partnership will deliver a high level of service to our customers.”

Previous Post

Strategies for the Resilient Perinatal Drug Supply Chain

Next Post

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Next Post
Merck to Acquire Verona

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In